XW10508
An editor has nominated this article for deletion. You are welcome to participate in the deletion discussion, which will decide whether or not to retain it. |
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| Clinical data | |
|---|---|
| Other names | XW10508; XW-10508 |
| Routes of administration | Oral[1][2][3] |
| Drug class | NMDA receptor antagonist; Antidepressant; Analgesic; Dissociative; Hallucinogen |
XW10508 is an orally active prodrug of esketamine, an NMDA receptor antagonist, which is under development for the treatment of major depressive disorder and chronic pain.[1][4][2][3] It is taken by mouth.[1][2][3]
The drug is a novel esketamine analogue and conjugate that acts as a prodrug of esketamine.[3] Esketamine, and by extension XW10508, is an NMDA receptor antagonist and indirect AMPA receptor activator.[1][5] XW10508 is being developed as once-daily orally administered extended-release and immediate-release formulations with misuse resistance.[1][3]
As of August 2024, XW10508 is in phase 2 clinical trials for major depressive disorder and is in phase 1 clinical trials for chronic pain.[1][4][2] However, no recent development has been reported for these indications.[1] The drug is being developed by XWPharma, which was previously known as XW Laboratories.[1][4][2] It is being developed in Australia.[1][2] The chemical structure of XW10508 does not yet seem to have been disclosed.[1]
References
[edit]- ^ a b c d e f g h i j "XW 10508". AdisInsight. 28 August 2024. Retrieved 2 November 2024.
- ^ a b c d e f "XW-10508 Drug Profile". Ozmosi. 13 April 2024. Retrieved 2 November 2024.
XW10508 is an internally discovered, investigational, orally bioavailable, once-daily glutamatergic providing NMDA receptor inhibition and AMPA receptor activation in development for the intended treatment of MDD and chronic pain.
- ^ a b c d e "XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain". GlobeNewswire News Room (Press release). 8 September 2021. Retrieved 2 November 2024.
- ^ a b c "Delving into the Latest Updates on XW-10508 with Synapse". Synapse. 1 November 2024. Retrieved 2 November 2024.
- ^ Jelen LA, Young AH, Stone JM (February 2021). "Ketamine: A tale of two enantiomers". J Psychopharmacol. 35 (2): 109–123. doi:10.1177/0269881120959644. PMC 7859674. PMID 33155503.